- 47 min ago How To Check Your Gas Cylinder Level With A Wet Cloth Trick
- 1 hr ago Toxoplasma Gondii, The Most 'Successful' Parasite In The World; Can Moms Pass This To Babies?
- 5 hrs ago Daily Horoscope, 16 May 2022: Today's Horoscope Predictions For All Zodiac Signs
- 21 hrs ago Got Thin Brittle Nails? Check Out These 8 Kitchen Ingredients That Can Help
- Technology Blur Tool On WhatsApp: How To Use Blur Tool On WhatsApp For iPhone?
- Movies Sutapa Sikdar Recalls Irrfan Khan's Reaction On Babil's Birth; 'The Smile On His Face Is Etched On My Mind'
- Finance With Over 44% SIP Returns, This Moderate Risky Hybrid Is Good For Investment: CRISIL Rated
- News Assam flood's first wave nearly 57,000 people in 7 districts, kills three | Key points
- Automobiles Top 10 Cars Sold In India In April 2022 - Maruti Continues To Dominate
- Sports IPL 2022: PBKS vs DC Dream11 Prediction, Fantasy Tips, Possible Playing 11, Match Prediction
- Travel Fun-filled Family Weekend Getaways Near Delhi
- Education CG Board Class 12th Result Out: Kunti Sao Becomes Topper With 98.20%
Stéphane Bancel, who is the CEO of pharmaceutical company Moderna, said in a panel session at the World Economic Forum in Davos that the company is soon planning to launch a combined booster vaccine shot of COVID-19, flu and respiratory syncytial virus (RSV) by the end of 2023 or say, before the start of the winter season of the year.
He said that a single annual booster vaccine of COVID-19, flu and RSV will be convenient for people who don't want to get two or three vaccine shots a winter. So, a combined dose of all the aforementioned infectious diseases will make sure that people get their vaccines on time.
He added that currently, the RSV program is in phase 3 and the flu program is in phase 2. So, in the best-case scenario, the vaccine could be ready by the fall of 2023. 
"I don't think it would happen in every country, but we believe it's possible to happen in some countries next year".
What To Know About The Flu Vaccine?
Flu is caused by influenza viruses that belong to the Orthomyxoviridae RNA virus family. It is divided into three types based on antigenic difference: influenza A, influenza B and influenza C.
Most of the seasonal flu epidemics are caused by influenza A and B viruses and result in millions of deaths worldwide. Influenza A virus is responsible for influenza pandemics at unpredictable intervals. 
The host for Influenza A virus could be migrating pigs, horses, birds and humans. The transmission between humans is mainly due to fomites (materials or objects such as furniture and clothes that carry infections). In the transmission of the influenza B virus, only human hosts are involved. Influenza C causes mild disease.
According to the CDC, the flu vaccine is required every year due to two main causes. Firstly, to boost a person's immunity as the effectiveness of the vaccine declines over time and secondly, to protect against the mutated influenza viruses.
What To Know About The RSV Vaccine?
RSV vaccine is given to protect against the respiratory syncytial virus that easily spread by contact with saliva, mucus or other respiratory droplets.
Young children and people with a compromised immune system are at increased risk of the infection. Symptoms of RSV include fever, chest congestion, difficulty breathing, cough, wheezing and runny nose, which typically begins within 3-7 days of the virus exposure. 
Currently, there is no approved vaccine for RSV but there are many promising vaccines that are under clinical trials. Medications such as palivizumab are available to reduce the symptoms and severity of the infection.
What To Know About The COVID-19 Vaccine?
According to COVID-19 vaccine statistics, around 392 crores of people are fully vaccinated, which is estimated to be 50.3 per cent of the population.
Along with that, there are around 36 countries that are now administering booster doses to fully vaccinated populations.
Vaccine boosters are administered because, over time, the effectiveness of the vaccine declines and a booster vaccine may help restore the immunity in the body to the required levels.
What Will Be The Effectiveness Of The Combined Vaccine Booster?
As the vaccine is still in the trial phase, currently, there is no data available on the effectiveness of the combined vaccine of COVID-19, flu and RSV.
"We're hoping in the March timeframe we should be able to have data to share with regulators to figure out the next step forward."
The vaccine is still in the phase 3 trial. The other details about the vaccine are not out yet, other than its timeline for the release, which is by the next year.
The COVID-19 pandemic may extend for the long term. As per a WHO official, the virus may end up becoming a part of the ecosystem. Therefore, to ensure the protection of people against the virus, vaccines must be administered on the entire population.
With other seasonal viruses like influenza and RSV, the COVID-19 may cause many fatalities. Therefore, a combined vaccine dose for all these three virus types can hopefully help reduce mortality and morbidity and may also lower public health emergencies.
- wellnessCovid-19 Virus Is Not Viable On Cash Banknotes, Study Finds
- wellnessNew Computer Model Can Help Assess Covid-19 Impact, Progression In Detail
- wellnessActive Covid-19 Cases In The Country Dip To 18,604
- diabetesDiabetes Almost Doubles The Risk Of Death From Covid-19: Study
- wellnessCovid-19 Cases May Rise In June-July, Speeding Up Vaccination Drive Best Way Ahead, Says Maharashtra Minister
- wellnessCovid-19 Severity Among Elderly May Be Due To Genetic Reasons, Study Reveals
- wellnessNew Plant-Based Covid Vaccine 70% Effective Against Variants: Study
- wellnessCovid Spread 1,000 Times More Likely From Air Than Surfaces: Study
- kidsPathways To Severe Coronavirus In Children Discovered By Scientists
- wellnessCovid-19 Not Over Yet Completely, Be Alert And Follow Govt's Guidelines: President Ram Nath Kovind
- healthCovid-19 Vaccination: SC Order States That 'No One Can Be Forced To Get Vaccinated:' 7 Main Points
- wellnessCovid-19: India Reports 3,688 New Infections, 50 Fatalities